Unusual Timeline of Nivolumab-induced Vitiligo in a Patient with Melanoma

Vitiligo, manifested by skin hypopigmentation, is an autoimmune disorder of the due to destruction melanocytes. Nivolumab, which a programmed cell death–1 receptor inhibitor, well-known therapy for melanoma. Nivolumab-induced vitiligo has been described in literature, explained non-cancerous This considered favorable response, correlated stronger immune response against tumor cells. The average onset reported be 5.2 months after starting therapy, with maximum being 9 months. We present 52-year-old male patient whose initial presentation occurred year and continued concluding Nivolumab therapy.